A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder.

ABSTRACT:

Background

Borderline personality disorder is associated with impaired quality of life and has a number of untoward public health associations. There is no established first-line pharmacological treatment for borderline personality disorder, and available options are not suitable for all individuals.

Aims

To evaluate brexpiprazole, which has effects on the dopaminergic and serotonergic systems, for the reduction of borderline personality disorder symptoms.

Method

Eighty adults with borderline personality disorder were recruited for a randomised, double-blind placebo-controlled study. Participants received 12-week treatment with brexpiprazole (1 mg/day for 1 week, then increasing to 2 mg/day) or placebo in a parallel design. The primary efficacy outcome measure was the

SUBMITTER: Grant JE 

PROVIDER: S-EPMC7612273 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature